Rasburicase
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00049 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 67 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hypouricemia, renal | KG + DL |
| 2 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | KG + DL |
| 3 | hepatic porphyria | KG + DL |
| 4 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 5 | primitive portal vein thrombosis | KG + DL |
| 6 | idiopathic copper-associated cirrhosis | KG + DL |
| 7 | hepatopulmonary syndrome | KG + DL |
| 8 | hepatoportal sclerosis | KG + DL |
| 9 | renal tubular acidosis | KG + DL |
| 10 | disorder of phenylalanine metabolism | KG + DL |
| 11 | disorder of tyrosine metabolism | KG + DL |
| 12 | teratogenic Pierre Robin syndrome | KG + DL |
| 13 | glycogen storage disease due to hepatic glycogen synthase deficiency | KG + DL |
| 14 | Lesch-Nyhan syndrome | KG + DL |
| 15 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | KG + DL |
| 16 | G6PD deficiency | KG + DL |
| 17 | inborn disorder of gamma-aminobutyric acid metabolism | KG + DL |
| 18 | inborn disorder of ornithine metabolism | KG + DL |
| 19 | inborn disorder of amino acid and other organic acid metabolism | KG + DL |
| 20 | inborn disorder of histidine metabolism | KG + DL |
| 21 | inborn disorder of serine family metabolism | KG + DL |
| 22 | cerebral creatine deficiency syndrome | KG + DL |
| 23 | genetic otorhinolaryngological malformation | KG + DL |
| 24 | inborn disorder of aspartate family metabolism | KG + DL |
| 25 | neonatal epileptic encephalopathy due to glutaminase deficiency | KG + DL |
| 26 | inborn disorder of tryptophan metabolism | KG + DL |
| 27 | 2-methylacetoacetyl CoA thiolase deficiency | KG + DL |
| 28 | semicircular canal dehiscence syndrome | KG + DL |
| 29 | idiopathic bilateral vestibulopathy | KG + DL |
| 30 | 3-hydroxyisobutyryl-CoA hydrolase deficiency | KG + DL |
| 31 | inborn disorder of phenylalanin or tyrosine metabolism | KG + DL |
| 32 | familial nasal acilia | KG + DL |
| 33 | tetrahydrobiopterin metabolic process disease | KG + DL |
| 34 | juvenile nasopharyngeal angiofibroma (disease) | KG + DL |
| 35 | silent sinus syndrome | KG + DL |
| 36 | 3-hydroxyisobutyric aciduria | KG + DL |
| 37 | maternal hyperthermia induced birth defects | KG + DL |
| 38 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 39 | cleft lip/palate-intestinal malrotation-cardiopathy syndrome | KG + DL |
| 40 | fetal trimethadione syndrome | KG + DL |
| 41 | craniorhiny | KG + DL |
| 42 | Bencze syndrome | KG + DL |
| 43 | phenobarbital embryopathy | KG + DL |
| 44 | fetal minoxidil syndrome | KG + DL |
| 45 | diabetic embryopathy | KG + DL |
| 46 | tibial aplasia-ectrodactyly syndrome | KG + DL |
| 47 | mandibulofacial dysostosis-macroblepharon-macrostomia syndrome | KG + DL |
| 48 | branchial cleft anomaly | KG + DL |
| 49 | galactokinase deficiency | KG + DL |
| 50 | velo-facial-skeletal syndrome | KG + DL |
(Showing top 50 of 67 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.